Connection

W. Garvey to Obesity

Back to Details
This is a "connection" page, showing publications W. Garvey has written about Obesity.
W. Garvey
Connection Strength
13.351
Obesity
  1. Economic outcomes of antiobesity medication use among adults in the United States: A retrospective cohort study. J Manag Care Spec Pharm. 2022 Oct; 28(10):1066-1079.
    View in: PubMed
    Score: 0.495
  2. Is Obesity or Adiposity-Based Chronic Disease Curable: The Set Point Theory, the Environment, and Second-Generation Medications. Endocr Pract. 2022 Feb; 28(2):214-222.
    View in: PubMed
    Score: 0.473
  3. Diagnosing Obesity as a First Step to Weight Loss: An Observational Study. Obesity (Silver Spring). 2020 12; 28(12):2305-2309.
    View in: PubMed
    Score: 0.438
  4. Response to "The Future of Obesity Diagnostic Coding". Obesity (Silver Spring). 2020 07; 28(7):1169-1170.
    View in: PubMed
    Score: 0.428
  5. In utero nutritional stress as a cause of obesity: Altered relationship between body fat, leptin levels and caloric intake in offspring into adulthood. Life Sci. 2020 Aug 01; 254:117764.
    View in: PubMed
    Score: 0.425
  6. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care. 2020 05; 43(5):1085-1093.
    View in: PubMed
    Score: 0.420
  7. Proposal for a Scientifically Correct and Medically Actionable Disease Classification System (ICD) for Obesity. Obesity (Silver Spring). 2020 03; 28(3):484-492.
    View in: PubMed
    Score: 0.420
  8. Core Principles, Treatment Standards, and Provider Competencies for the Care of Patients with Obesity. Obesity (Silver Spring). 2019 07; 27(7):1045-1047.
    View in: PubMed
    Score: 0.401
  9. Leptin, An Adipokine With Central Importance in the Global Obesity Problem. Glob Heart. 2018 06; 13(2):113-127.
    View in: PubMed
    Score: 0.360
  10. Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release. Diabetes Care. 2017 07; 40(7):856-862.
    View in: PubMed
    Score: 0.345
  11. The Adipokine-Cardiovascular-Lifestyle Network: Translation to Clinical Practice. J Am Coll Cardiol. 2016 10 18; 68(16):1785-1803.
    View in: PubMed
    Score: 0.332
  12. Trends in Cardiovascular Health Metrics in Obese Adults: National Health and Nutrition Examination Survey (NHANES), 1988-2014. J Am Heart Assoc. 2016 07 13; 5(7).
    View in: PubMed
    Score: 0.326
  13. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITYEXECUTIVE SUMMARYComplete Guidelines available at https://www.aace.com/publications/guidelines. Endocr Pract. 2016 07; 22(7):842-84.
    View in: PubMed
    Score: 0.325
  14. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. Endocr Pract. 2016 Jul; 22 Suppl 3:1-203.
    View in: PubMed
    Score: 0.323
  15. Cardiometabolic disease risk in metabolically healthy and unhealthy obesity: Stability of metabolic health status in adults. Obesity (Silver Spring). 2016 Feb; 24(2):516-25.
    View in: PubMed
    Score: 0.314
  16. Weight maintenance: challenges, tools and strategies for primary care physicians. Obes Rev. 2016 Jan; 17(1):81-93.
    View in: PubMed
    Score: 0.310
  17. Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action. Curr Obes Rep. 2015 Jun; 4(2):287-302.
    View in: PubMed
    Score: 0.302
  18. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014 Dec; 37(12):3309-16.
    View in: PubMed
    Score: 0.288
  19. A complications-based clinical staging of obesity to guide treatment modality and intensity. Curr Opin Endocrinol Diabetes Obes. 2013 Oct; 20(5):377-88.
    View in: PubMed
    Score: 0.269
  20. The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obesity (Silver Spring). 2014 Jan; 22(1):110-8.
    View in: PubMed
    Score: 0.268
  21. New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach. Endocr Pract. 2013 Sep-Oct; 19(5):864-74.
    View in: PubMed
    Score: 0.268
  22. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opin Drug Saf. 2013 Sep; 12(5):741-56.
    View in: PubMed
    Score: 0.263
  23. New options for the treatment of obesity and type 2 diabetes mellitus (narrative review). J Diabetes Complications. 2013 Sep-Oct; 27(5):508-18.
    View in: PubMed
    Score: 0.263
  24. American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. Endocr Pract. 2012 Sep-Oct; 18(5):642-8.
    View in: PubMed
    Score: 0.250
  25. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012 Feb; 95(2):297-308.
    View in: PubMed
    Score: 0.237
  26. Effects of short-term very low-calorie diet on intramyocellular lipid and insulin sensitivity in nondiabetic and type 2 diabetic subjects. Metabolism. 2008 Jan; 57(1):1-8.
    View in: PubMed
    Score: 0.181
  27. Diet, insulin resistance, and obesity: zoning in on data for Atkins dieters living in South Beach. J Clin Endocrinol Metab. 2004 Sep; 89(9):4197-205.
    View in: PubMed
    Score: 0.143
  28. Role of UCP2 and UCP3 in nutrition and obesity. Nutrition. 2004 Jan; 20(1):139-44.
    View in: PubMed
    Score: 0.137
  29. Clinical and Cost Benefits of Anti-Obesity Medication for US Veterans Participating in the MOVE! Weight Management Program. Popul Health Manag. 2023 02; 26(1):72-82.
    View in: PubMed
    Score: 0.129
  30. Two-year effect of semaglutide 2.4?mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring). 2023 03; 31(3):703-715.
    View in: PubMed
    Score: 0.128
  31. Burden of illness associated with overweight and obesity in patients hospitalized with COVID-19 in the United States: analysis of the premier healthcare database from April 1, 2020 to October 31, 2020. J Med Econ. 2023 Jan-Dec; 26(1):376-385.
    View in: PubMed
    Score: 0.128
  32. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022 10; 28(10):2083-2091.
    View in: PubMed
    Score: 0.126
  33. Examining the evidence for weight management in individuals with type 2 diabetes. Diabetes Obes Metab. 2022 08; 24(8):1411-1422.
    View in: PubMed
    Score: 0.123
  34. New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications. J Clin Endocrinol Metab. 2022 03 24; 107(4):e1339-e1347.
    View in: PubMed
    Score: 0.121
  35. Building Successful Models in Primary Care to Improve the Management of Adult Patients with Obesity. Popul Health Manag. 2021 10; 24(5):548-559.
    View in: PubMed
    Score: 0.113
  36. Exercise training and diet-induced weight loss increase markers of hepatic bile acid (BA) synthesis and reduce serum total BA concentrations in obese women. Am J Physiol Endocrinol Metab. 2021 05 01; 320(5):E864-E873.
    View in: PubMed
    Score: 0.112
  37. Impact of a weight loss and fitness intervention on exercise-associated plasma oxylipin patterns in obese, insulin-resistant, sedentary women. Physiol Rep. 2020 09; 8(17):e14547.
    View in: PubMed
    Score: 0.109
  38. Development and validation of a model for predicting incident type 2 diabetes using quantitative clinical data and a Bayesian logistic model: A nationwide cohort and modeling study. PLoS Med. 2020 08; 17(8):e1003232.
    View in: PubMed
    Score: 0.108
  39. Covid-19 & Obesity: Beyond Bmi. Endocr Pract. 2020 Aug; 26(8):923-925.
    View in: PubMed
    Score: 0.108
  40. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring). 2020 06; 28(6):1050-1061.
    View in: PubMed
    Score: 0.107
  41. Race affects the association of obesity measures with insulin sensitivity. Am J Clin Nutr. 2020 03 01; 111(3):515-525.
    View in: PubMed
    Score: 0.105
  42. Changes in weight control behaviors and hedonic hunger in a commercial weight management program adapted for individuals with type 2 diabetes. Int J Obes (Lond). 2020 05; 44(5):990-998.
    View in: PubMed
    Score: 0.104
  43. CLINICAL PRACTICE GUIDELINES FOR THE PERIOPERATIVE NUTRITION, METABOLIC, AND NONSURGICAL SUPPORT OF PATIENTS UNDERGOING BARIATRIC PROCEDURES - 2019 UPDATE: COSPONSORED BY AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY, THE OBESITY SOCIETY, AMERICAN SOCIETY FOR METABOLIC & BARIATRIC SURGERY, OBESITY MEDICINE ASSOCIATION, AND AMERICAN SOCIETY OF ANESTHESIOLOGISTS - EXECUTIVE SUMMARY. Endocr Pract. 2019 Dec; 25(12):1346-1359.
    View in: PubMed
    Score: 0.103
  44. Exercise plasma metabolomics and xenometabolomics in obese, sedentary, insulin-resistant women: impact of a fitness and weight loss intervention. Am J Physiol Endocrinol Metab. 2019 12 01; 317(6):E999-E1014.
    View in: PubMed
    Score: 0.102
  45. COMMENTARY FROM THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS ON THE U.S. PREVENTIVE SERVICES TASK FORCE RECOMMANDATIONS REGARDING WEIGHT LOSS INTERVENTIONS. Endocr Pract. 2019 04; 25(4):394-395.
    View in: PubMed
    Score: 0.099
  46. DYSGLYCEMIA-BASED CHRONIC DISEASE: AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS POSITION STATEMENT. Endocr Pract. 2018 Nov; 24(11):995-1011.
    View in: PubMed
    Score: 0.096
  47. Effects of mutations in the human uncoupling protein 3 gene on the respiratory quotient and fat oxidation in severe obesity and type 2 diabetes. J Clin Invest. 1998 Oct 01; 102(7):1345-51.
    View in: PubMed
    Score: 0.095
  48. Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12-Week Treatment: A Randomized Substudy. Obesity (Silver Spring). 2018 02; 26(2):332-339.
    View in: PubMed
    Score: 0.091
  49. APPLICATION OF THE AACE/ACE ADVANCED FRAMEWORK FOR THE DIAGNOSIS OF OBESITY AND CARDIOMETABOLIC DISEASE STAGING IN A GENERAL POPULATION FROM 3 REGIONS OF VENEZUELA: THE VEMSOLS STUDY RESULTS. Endocr Pract. 2018 Jan; 24(1):6-13.
    View in: PubMed
    Score: 0.089
  50. Obesity: Obesity and cardiometabolic disease - more than meets the eye. Nat Rev Endocrinol. 2017 10; 13(10):566-568.
    View in: PubMed
    Score: 0.088
  51. Pharmacotherapy for Weight Management in the VHA. J Gen Intern Med. 2017 Apr; 32(Suppl 1):70-73.
    View in: PubMed
    Score: 0.086
  52. Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial. J Diabetes Complications. 2017 May; 31(5):891-897.
    View in: PubMed
    Score: 0.085
  53. ADIPOSITY-BASED CHRONIC DISEASE AS A NEW DIAGNOSTIC TERM: THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT. Endocr Pract. 2017 Mar; 23(3):372-378.
    View in: PubMed
    Score: 0.084
  54. Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders. Postgrad Med. 2016 Aug; 128(6):591-7.
    View in: PubMed
    Score: 0.082
  55. AACE response to a candid discussion of obesity. Am J Med. 2015 Oct; 128(10):e57.
    View in: PubMed
    Score: 0.077
  56. Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care. 2015 Aug; 38(8):1567-82.
    View in: PubMed
    Score: 0.076
  57. Glucose transporter proteins and insulin sensitivity in humans. Braz J Med Biol Res. 1994 Apr; 27(4):933-9.
    View in: PubMed
    Score: 0.070
  58. Genome-wide association of body fat distribution in African ancestry populations suggests new loci. PLoS Genet. 2013; 9(8):e1003681.
    View in: PubMed
    Score: 0.067
  59. A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet. 2013 Jun; 45(6):690-6.
    View in: PubMed
    Score: 0.065
  60. In response. Endocr Pract. 2013 Jan-Feb; 19(1):170.
    View in: PubMed
    Score: 0.064
  61. Gene expression of GLUT4 in skeletal muscle from insulin-resistant patients with obesity, IGT, GDM, and NIDDM. Diabetes. 1992 Apr; 41(4):465-75.
    View in: PubMed
    Score: 0.061
  62. Noggin is novel inducer of mesenchymal stem cell adipogenesis: implications for bone health and obesity. J Biol Chem. 2012 Apr 06; 287(15):12241-9.
    View in: PubMed
    Score: 0.060
  63. Intramyocellular lipid and insulin resistance: differential relationships in European and African Americans. Obesity (Silver Spring). 2011 Jul; 19(7):1469-75.
    View in: PubMed
    Score: 0.056
  64. Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity. J Clin Invest. 1991 Mar; 87(3):1072-81.
    View in: PubMed
    Score: 0.056
  65. Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS One. 2010 Dec 10; 5(12):e15234.
    View in: PubMed
    Score: 0.055
  66. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr. 2009 Jun; 139(6):1073-81.
    View in: PubMed
    Score: 0.049
  67. Intracellular lipid accumulation in liver and muscle and the insulin resistance syndrome. Endocrinol Metab Clin North Am. 2008 Dec; 37(4):841-56.
    View in: PubMed
    Score: 0.048
  68. Correlation of in vivo and in vitro actions of insulin in obesity and noninsulin-dependent diabetes mellitus: role of the glucose transport system. Diabetes Metab Rev. 1988 Sep; 4(6):543-69.
    View in: PubMed
    Score: 0.047
  69. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol. 2007 Jun; 18(3):263-70.
    View in: PubMed
    Score: 0.043
  70. Obesity and Overweight: Probing Causes, Consequences, and Novel Therapeutic Approaches Through the American Heart Association's Strategically Focused Research Network. J Am Heart Assoc. 2023 Feb 21; 12(4):e027693.
    View in: PubMed
    Score: 0.032
  71. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2023 02; 25(2):468-478.
    View in: PubMed
    Score: 0.032
  72. French-fried potato consumption and energy balance: a randomized controlled trial. Am J Clin Nutr. 2022 06 07; 115(6):1626-1636.
    View in: PubMed
    Score: 0.031
  73. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022 May; 28(5):528-562.
    View in: PubMed
    Score: 0.030
  74. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 01 11; 327(2):138-150.
    View in: PubMed
    Score: 0.030
  75. Case presentation and panel discussion: Cardiometabolic risk mitigation. JPEN J Parenter Enteral Nutr. 2021 11; 45(S2):93-99.
    View in: PubMed
    Score: 0.029
  76. Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesity-Reply. JAMA. 2021 09 28; 326(12):1214-1215.
    View in: PubMed
    Score: 0.029
  77. A role for the Agouti-Related Protein promoter in obesity and type 2 diabetes. Biochem Biophys Res Commun. 2001 Sep 21; 287(2):568-73.
    View in: PubMed
    Score: 0.029
  78. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 04 13; 325(14):1403-1413.
    View in: PubMed
    Score: 0.028
  79. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Surg Obes Relat Dis. 2020 Feb; 16(2):175-247.
    View in: PubMed
    Score: 0.026
  80. Expression of mRNAs encoding uncoupling proteins in human skeletal muscle: effects of obesity and diabetes. Diabetes. 1998 Dec; 47(12):1935-40.
    View in: PubMed
    Score: 0.024
  81. An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians. Am J Hum Genet. 1998 Oct; 63(4):1130-8.
    View in: PubMed
    Score: 0.024
  82. Structure and organization of the human uncoupling protein 2 gene and identification of a common biallelic variant in Caucasian and African-American subjects. Diabetes. 1998 Apr; 47(4):685-7.
    View in: PubMed
    Score: 0.023
  83. Autosomal genomic scan for loci linked to obesity and energy metabolism in Pima Indians. Am J Hum Genet. 1998 Mar; 62(3):659-68.
    View in: PubMed
    Score: 0.023
  84. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. Endocr Pract. 2018 01; 24(1):91-120.
    View in: PubMed
    Score: 0.023
  85. Clinical implications of the insulin resistance syndrome. Clin Cornerstone. 1998; 1(3):13-28.
    View in: PubMed
    Score: 0.023
  86. The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab. 1997 Apr; 82(4):1293-300.
    View in: PubMed
    Score: 0.021
  87. Genomewide search for genes influencing percent body fat in Pima Indians: suggestive linkage at chromosome 11q21-q22. Pima Diabetes Gene Group. Am J Hum Genet. 1997 Jan; 60(1):166-73.
    View in: PubMed
    Score: 0.021
  88. Acylcarnitines as markers of exercise-associated fuel partitioning, xenometabolism, and potential signals to muscle afferent neurons. Exp Physiol. 2017 01 01; 102(1):48-69.
    View in: PubMed
    Score: 0.021
  89. EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS. Endocr Pract. 2016 11; 22(11):1277-1287.
    View in: PubMed
    Score: 0.020
  90. TRANSCULTURALIZATION RECOMMENDATIONS FOR DEVELOPING LATIN AMERICAN CLINICAL PRACTICE ALGORITHMS IN ENDOCRINOLOGY--PROCEEDINGS OF THE 2015 PAN-AMERICAN WORKSHOP BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY. Endocr Pract. 2016 Apr; 22(4):476-501.
    View in: PubMed
    Score: 0.020
  91. The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest. 1996 Feb 15; 97(4):1111-6.
    View in: PubMed
    Score: 0.020
  92. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. Endocr Pract. 2016 Jan; 22(1):84-113.
    View in: PubMed
    Score: 0.020
  93. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. Endocr Pract. 2015 Dec; 21(12):1403-14.
    View in: PubMed
    Score: 0.020
  94. KSRP ablation enhances brown fat gene program in white adipose tissue through reduced miR-150 expression. Diabetes. 2014 Sep; 63(9):2949-61.
    View in: PubMed
    Score: 0.017
  95. Improved metabolic health alters host metabolism in parallel with changes in systemic xeno-metabolites of gut origin. PLoS One. 2014; 9(1):e84260.
    View in: PubMed
    Score: 0.017
  96. Cellular insulin action and insulin resistance. Baillieres Clin Endocrinol Metab. 1993 Oct; 7(4):785-873.
    View in: PubMed
    Score: 0.017
  97. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract. 2013 May-Jun; 19(3):536-57.
    View in: PubMed
    Score: 0.016
  98. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr; 19(2):327-36.
    View in: PubMed
    Score: 0.016
  99. Type 2 diabetes associated changes in the plasma non-esterified fatty acids, oxylipins and endocannabinoids. PLoS One. 2012; 7(11):e48852.
    View in: PubMed
    Score: 0.016
  100. Adult mice maintained on a high-fat diet exhibit object location memory deficits and reduced hippocampal SIRT1 gene expression. Neurobiol Learn Mem. 2012 Jul; 98(1):25-32.
    View in: PubMed
    Score: 0.015
  101. Role of glucose transporters in the cellular insulin resistance of type II non-insulin-dependent diabetes mellitus. J Clin Invest. 1988 May; 81(5):1528-36.
    View in: PubMed
    Score: 0.012
  102. New insights into the metabolic regulation of insulin action and insulin resistance: role of glucose and amino acids. FASEB J. 1991 Dec; 5(15):3031-6.
    View in: PubMed
    Score: 0.004
  103. Cellular mechanisms of insulin resistance in non-insulin-dependent (type II) diabetes. Am J Med. 1988 Nov 28; 85(5A):86-105.
    View in: PubMed
    Score: 0.003
  104. Insulin resistance in non-insulin dependent (type II) and insulin dependent (type I) diabetes mellitus. Adv Exp Med Biol. 1985; 189:176-205.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.